Literature DB >> 21574101

Nephrotic syndrome and neoplasia: our experience and review of the literature.

Małgorzata Wągrowska-Danilewicz1, Marian Danilewicz.   

Abstract

The glomerular lesion of paraneoplastic nephrotic syndrome usually presents as membranous nephropathy, minimal change disease or membranoproliferative glomerulonephritis. We present six cases of paraneoplastic nephrotic syndrome. Four cases were associated with epithelial malignancies (lung, gastric and colon cancer), and two cases with lymphoproliferative malignancies (Hodgkin's lymphoma and chronic lymphocytic leukemia). On the basis of light microscopy, immunofluorescence study and electron microscopy, membranous nephropathy, minimal change disease, and membranoproliferative glomerulopathy were established. We concluded, that the search for malignancy is warranted in patients over the age of 55 presenting with nephrotic syndrome, particularly in cases of membranous nephropathy.

Entities:  

Mesh:

Year:  2011        PMID: 21574101

Source DB:  PubMed          Journal:  Pol J Pathol        ISSN: 1233-9687            Impact factor:   1.072


  5 in total

1.  A rare case of atypical chronic lymphocytic leukaemia presenting as nephrotic syndrome.

Authors:  Martina Soldarini; Lucia Farina; Augusto Genderini; Niccolo Bolli
Journal:  BMJ Case Rep       Date:  2017-07-14

Review 2.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

3.  A case of membranous glomerulopathy associated with lung cancer and review of the literature.

Authors:  Aydin Aytekin; Ahmet Ozet; Irem Bilgetekin; Betul Ogut; Aydin Ciltas; Mustafa Benekli
Journal:  Mol Clin Oncol       Date:  2017-06-21

4.  Nephrotic syndrome and Hodgkin lymphoma in children. Report of two cases.

Authors:  A Pourtsidis; D Doganis; M Baka; M Varvoutsi; H Kosmidis
Journal:  Hippokratia       Date:  2014 Oct-Dec       Impact factor: 0.471

Review 5.  Considering renal risk while managing cancer.

Authors:  Vahakn B Shahinian; Amit Bahl; Daniela Niepel; Vito Lorusso
Journal:  Cancer Manag Res       Date:  2017-05-16       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.